Clinical experience with sesame oral immunotherapy and a quality-of-life assessment

Background:

Allergic reactions to sesame have increased in prevalence in the United States. Sesame oral immunotherapy (OIT) is an emerging management strategy. Few reports assessed the benefits and risks of sesame OIT in children with sesame allergy.

Objective:

To study the adverse events and quality of life (QoL) on sesame OIT in a U.S. population.

Methods:

Twenty-three patient charts were retrospectively reviewed from 2017 to 2020. The patients received a validated Food Allergy Quality of Life Questionnaire and a survey on adverse reactions during maintenance therapy. Patients who were 8.5 ± 4.7 years of age (30% girls and 70% boys) with a documented history of sesame allergy and who had undergone sesame OIT were reviewed.

Results:

The buildup phase was 293.7 ± 87.1 days. Twenty-one of the 23 patients (91.3%) reached maintenance therapy. Twenty-one patients (91.3%) had at least one gastrointestinal reaction; 18 (78.3%) had at least one cutaneous reaction; 6 (26%) had at least one respiratory reaction. Age raised the odds of gastrointestinal reactions more than fivefold (odds ratio [OR] 5.653 (95% confidence interval [CI], 2.409 ‐ 13.269); p = 0.0009). Asthma boosted the odds of respiratory reactions of more than ninefold (OR 9.206 [95% CI, 1.535 ‐ 55.211]; p = 0.0187). Female gender increased the odds of having a respiratory reaction by more than sevenfold (OR 7.545 [95% CI, 1.207 ‐ 47.153]; p = 0.0330). Asthma amplified the odds of cutaneous reactions (OR 11.725 [95% CI, 2.390 ‐ 57.517]; p = 0.0053). Three patients ultimately discontinued therapy. Food-related anxiety (‐0.773) and social/dietary limitation (‐0.687) improved significantly in QoL.

Conclusion:

Sesame OIT may be safe and easily adaptable to private practice and significantly improves QoL. Further prospective studies would be helpful to fully assess these relationships.